The Sarcoma Alliance for Research Through Collaboration (SARC) announced that Dr. Jonathan Fletcher has been appointed chief scientific officer.
This is a new role at the nonprofit cancer research organization, which leads collaborative discovery, translational research, and clinical trials in sarcoma, a form of cancer that impacts children and adults.
As CSO, Fletcher will expand SARCs commitments in sarcoma biology, discovery science, and biomarkers, thereby strengthening its portfolio of clinical trials. State-of-the-art correlative science studies will continue to be a priority, and efforts to maximize clinical trial data-sharing with the scientific community will be increased.
“Dr. Fletcher is an inspirational leader in sarcoma research and, apropos to this appointment, is widely recognized for his commitment to advancing the team science efforts which are so key to accelerating discoveries from the lab to the clinic,” says Steven Young, president and CEO of SARC.
“SARC welcomes the opportunity to further deepen Dr. Fletcher’s hands-on engagement supporting our mission to convert sarcoma biologic discoveries into more effective treatments.”
Fletcher will also serve as chief spokesperson for SARC’s scientific strategy, translating sarcoma science for diverse audiences such as the NIH, patient advocates, sarcoma clinicians, and SARC industry partners.
“SARC fosters multi-institutional collaborations, providing expertise in clinical trials, biostatistics, and biospecimen processing,” says Fletcher. “We now aim to expand SARC’s commitment to discovery and translational sciences.
“One goal is to integrate more science in each SARC clinical trial, explaining why new therapies help some people and not others. This will enable us to refine the therapeutic approaches, helping more people and reducing needless treatment toxicity.”